登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Nuclease >GMP-NUES19

GMP GENIUS™Nuclease DMF

PG version NUE-S5119 is now available for seamless transition.
热门推荐产品:配套残留检测试剂盒

优势特色(Features)

  1. Designed under ISO 9001:2015 and ISO 13485:2016
  2. Manufactured and QC tested under a GMP compliance factory
  3. FDA DMF filed
  4. Animal-Free materials
  5. Beta-lactam materials free
  6. Batch-to-batch consistency
  7. Stringent quality control tests
  8. No animal derived peptone and lactose used in production process

产品描述(Product Details)

GMP GENIUS™Nuclease is a tag-free recombinant form of Serratia marcescens extracellular endonuclease produced in Escherichia coli using a proprietary process at ACRObiosystems. GMP GENIUS™Nuclease performs optimally at low and physiological salt concentrations (0-200 mM NaCl). The product is a homodimer with monomer molecular masses of about 30 kDa. The enzyme is a non-specific nuclease with high specific activity, degrading single- and double-stranded nucleic acids in any form (single stranded, double stranded, linear, circular, and supercoiled). It hydrolyzes internal phosphodiester bonds present between the nucleotides to 5’- phosphorylated oligonucleotides of 3-5 bases in length.

应用说明(Application)

Elimination of nucleic acids from biologics, optimal for samples with 0-200 mM salt in presence of 2-10 mM Mg++

• clinical viral vaccine production

• clinical viral vector production for cell and gene therapy (CGT)

• Other clinical development and production uses

反应条件(Operating Conditions)

GMP GENIUS™Nuclease is functional between pH 6 and 10 (optimal at pH8 - 8.5) , and from 0°C to 50 °C (optimal at 37 °C - 45 °C). Mg2+ (1-2 mM) is required for enzyme activity.1 mM EDTA reduced the activity by 30% in the presence of 1 mM MgCl2; 0.1 M EDTA eliminated all enzyme activity. In the presence of 1 mM MgCl2, enzyme levels were reduced 75% by 0.1 M CaCl2 or 1 M NaCl. Under standard assay conditions, 1 mM iodoacetate had no effect on the enzymatic rate, whereas 1 mM mercaptoethanol and maleic acid reduced the activity by only 5 to 10%. 10 mM p- Chloromercurybenzoate completely inactivates the enzyme, while 0.64 M beta-mercaptoethanol in the presence of 2 M urea causes only partial inactivation of the enzyme. 4 or 7 M Urea increases the enzyme activity.

纯度(Purity)

>95% as determined by SDS-PAGE.

>99% as determined by SEC-HPLC.

酶活(Enzyme Activity)

≥250 U/μL

宿主蛋白残留(Host Cell Protein)

<0.05 ng/µg of protein tested by ELISA.

蛋白酶活性(Protease Activity)

Negative.

无菌(Sterility)

The sterility testing was performed by membrane filtration method described in CP<1101>, USP<71> and Eur. Ph. 2.6.1.

支原体(Mycoplasma)

Negative.

内毒素(Endotoxin)

Less than 10 EU/mg by the LAL method.

重金属残留(Heavy Metals)

≤10 ppm

制剂(Formulation)

Supplied as 0.2 μm filtered solution in 20 mM Tris, 20 mM NaCl, 2 mM MgCl2, pH8.0.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

This product is stable after storage at:

  1. The product MUST be stored at -20°C or lower upon receipt;
  2. -20°C for 5 years under sterile conditions.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Nuclease SDS-PAGE

The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-HPLC

Nuclease SEC-HPLC

The purity of GMP GENIUS™Nuclease (Cat. No. GMP-NUES19) was greater than 99% as determined by SEC-HPLC.

 

活性(Bioactivity)

Specific activity for GMP GENIUS Nuclease is measured under standard assay conditions. The specific activity of GMP GENIUS Nuclease, is > 1.2 x 10^6 unit/mg protein (QC tested). One unit will digest sonicated salmon sperm DNA to acid-soluble oligonucleotides equivalent to a ΔA260 of 1.0 in 30 min at pH 8.0 at 37 °C, which corresponds approximately to complete digestion of 37 μg DNA,Note that 1 KU=1000 units.

Nuclease ENZYME

GMP GENIUS Nuclease shows high specific activity.

Nuclease ENZYME

The effect of Mg++ concentrations on GENIUS™Nuclease activity. The Nuclease requires 1-2 mM Mg++ cations for optimal activity.

 

稳定性(Stability)

Nuclease STABILITY

The specific activity shows that GMP GENIUS™Nuclease (Cat. No. GMP-NUES19) is stable in different batches.

Nuclease STABILITY

The specific activity shows that GMP GENIUS™Nuclease (Cat. No. GMP-NUES19) is stable after 3 freeze-thaws.

 

MANUFACTURING SPECIFICATIONS

ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP <92> Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP <1043> Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.


ACROBiosystems Quality Management System Contents:

  1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory.
  2. Animal-Free materials
  3. Materials purchased from the approved suppliers by QA
  4. ISO 5 clean rooms and automatic filling equipment
  5. Qualified personnel
  6. Quality-related documents review and approve by QA
  7. Fully batch production and control records
  8. Equipment maintenance and calibration
  9. Validation of analytical procedures
  10. Stability studies conducted
  11. Comprehensive regulatory support files

Request For Regulatory Support Files(RSF)  Request For DMF


ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

  1. SDS-PAGE
  2. Protein content
  3. Endotoxin level
  4. Residual Host Cell DNA content
  5. Residual Host Cell Protein content
  6. Biological activity analysis
  7. Microbial testing
  8. Mycoplasma testing
  9. In vitro virus assay
  10. Batch-to-batch consistency


DISCLAIMER

ACROBiosystems GMP grade products are designed for research, manufacturing use or ex vivo use. CAUTION: Not intended for direct human use.

TERMS AND CONDITIONS

All products are warranted to meet ACROBiosystems Inc.’s (“ACRO”) published specifications when used under normal laboratory conditions.


ACRO DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, ACRO DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOT WITH STANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN ACRO AND PURCHASER FOR THE PURCAHSE OF THE PRODUCTS, ACRO’S TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO ACRO FOR THE RELEVANT PRODUCTS. IN NO EVENT WILL ACRO BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

The End User is aware that ACROBiosystems Inc. and its affiliate (“ACRO”) sell GMP grade products designed for research, manufacturing use or ex vivo use and not intended for human in vivo applications. The End User further agrees, as a condition of the sales of ACRO’s GMP grade products that: a) the End User will not use this GMP grade product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the applicable review board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

 
评论(0)
 
ACRO质量管理体系
 
 

前沿进展

DNA Aptamers with Chemically Locked Ends for Virus Infection Inhibition
Song, Li, Dong et al
ACS Appl Mater Interfaces (2025)
Abstract: Nucleic acid aptamers, known as chemical antibodies, demonstrate remarkable affinity and specificity for targets. Therefore, aptamers are proposed as an alternative to an antibody in extensive applications. However, nucleic acid aptamers exhibit poor tolerance to degradation by nucleases, which severely hampers their biological applications. Herein, we developed a biological regulation pattern for aptamers by utilizing small-molecule-mediated terminal manipulation, which could prevent the interaction of DNA aptamers with exonucleases and help aptamers persist in the desired conformation with high stability. Diagonal T-T bases were designed in the ends of aptamers and could be chemically cross-linked with trioxsalen via photocatalyzed cycloaddition. Aptamers with different patterns of terminal T-T cross-linking sites were synthesized. Experimental investigation and molecular dynamics simulations combinedly revealed that the cross-linking efficiency of ends depended on multiple factors: (i) the number of T-T cross-linking sites in the terminal sequences, (ii) the spatial conformation of aptamers, and (iii) the competitive binding ability of the T-T sites with trioxsalen compared to other base sites. The aptamers with locked ends exhibited superior exonuclease resistance, especially with both 3'- and 5'-cross-linked ends, thus demonstrating a great target binding capability. Notably, in the application exploration, the terminal locked aptamers, which bound to receptor-binding domains on SARS-CoV-2, showed superior performance in virus infection inhibition. This work puts forward a paradigm to develop a biological regulation pattern for aptamers based on chemical terminal manipulation of DNA, potentially promoting the clinical applications of nucleic acid drugs.
Disruption of CYP88B1 by transcription activator-like effector nuclease in potato and potential use to produce useful saponins
Yasumoto, Lee, Akiyama et al
Plant Biotechnol (Tokyo) (2024) 41 (3), 289-293
Abstract: Potatoes produce steroidal glycoalkaloids (SGAs), toxic secondary metabolites associated with food poisoning. SGAs are synthesized by multiple biosynthetic enzymes. Knockdown of the CYP88B1 gene, also known as PGA3 or GAME4, is predicted to reduce toxic SGAs and accumulate steroidal saponins. These saponins not only serve as a source of steroidal drugs but are also anticipated to confer disease resistance to potatoes. In this study, we employed transcription activator-like effector nucleases (TALENs) for genome editing to disrupt CYP88B1. We introduced the TALEN expression vector via Agrobacterium-mediated transformation into seven potato lines. In six of these lines, disruption of the CYP88B1 gene was confirmed. Liquid chromatography-mass spectrometry analysis revealed that SGAs were reduced to undetectable levels, corroborating the accumulation of steroidal saponins observed in previous knockdown studies. Our findings demonstrate the feasibility of generating low-toxicity potato lines through CYP88B1 gene disruption using genome editing techniques.© 2024 Japanese Society for Plant Biotechnology.
Non-invasive detection of allele-specific CRISPR-SaCas9-KKH disruption of TOR1A DYT1 allele in a xenograft mouse model
Maalouf, Frederick, Sharma et al
Mol Ther Nucleic Acids (2025) 36 (1), 102466
Abstract: DYT1 dystonia is a neurological movement disorder characterized by a dominant 3-base pair deletion (ΔGAG) in the TOR1A gene. This study demonstrates a gene-editing approach that selectively targets the ΔGAG mutation in the TOR1A DYT1 allele while safeguarding the wild-type (WT) TOR1A allele. We optimized an adeno-associated virus (AAV) vector-compatible variant of the Staphylococcus aureus Cas9 nuclease ortholog (SaCas9-KKH) in DYT1 patient-derived human neuronal progenitor cells (hNPCs). On-target editing of the TOR1A DYT1 allele was confirmed at the genomic level from brain tissue in a xenograft mouse model. To avoid brain biopsy for demonstrating TOR1A DYT1 editing, we developed a non-invasive monitoring method using extracellular RNA (exRNA). TOR1A exRNA was retrieved from the extracellular vesicle (EV) secretions of hNPCs and plasma samples, indicating whether the donor was a TOR1A DYT1 carrier. This technique enabled us to assess AAV-mediated disruption of the TOR1A DYT1 allele in the brains of mice using blood samples.© 2025 The Authors.
Post-replicative lesion processing limits DNA damage-induced mutagenesis
Masłowska, Wong, Ulrich et al
Nucleic Acids Res (2025) 53 (6)
Abstract: DNA lesions are a threat to genome stability. To cope with them during DNA replication, cells have evolved lesion bypass mechanisms: Translesion Synthesis (TLS), which allows the cell to insert a nucleotide directly opposite the lesion, with the risk of introducing a mutation, and error-free damage avoidance (DA), which uses homologous recombination to retrieve the genetic information from the sister chromatid. In this study, we investigate the timing of lesion bypass in yeast and its implications for the accuracy of the process. Our findings reveal that DNA polymerase η can bypass common, UV-induced cyclobutane pyrimidine dimers at the fork, immediately after encountering the blocking lesion. In contrast, TLS at (6-4) photoproducts and bulky G-AAF adducts, mediated by Rev1 and Pol ζ, takes place behind the fork, at post-replicative gaps that are generated downstream of the lesion after repriming. We show that in this latter situation, TLS competes with the DA pathway, thus reducing overall mutagenicity of damage bypass. Additionally, our study demonstrates that Exo1 nuclease influences the balance between TLS and DA by modulating the size of the post-replicative gaps.© The Author(s) 2025. Published by Oxford University Press on behalf of Nucleic Acids Research.
Showing 1-4 of 32685 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定